Unchained Labs is a technology company.
Unchained Labs has raised $80.0M across 4 funding rounds.
Unchained Labs has raised $80.0M in total across 4 funding rounds.
Unchained Labs has raised $80.0M in total across 4 funding rounds.
Unchained Labs's investors include Canaan Partners, Norwest Venture Partners.
Unchained Labs is a life sciences technology company that develops specialized tools for biologics and gene therapy research, enabling scientists to prepare, process, and characterize complex biological samples like proteins, viruses, and nanoparticles.[1][2][3] It serves pharmaceutical companies, biotechnology firms, and academic research institutions by solving key challenges in stability screening, concentration measurement, buffer exchange, and vector characterization, with products such as the Uncle platform for multi-measurement stability analysis and Stunner for nanoparticle payload quantification and sizing.[1][2][4] The company, founded around 2014-2015 and based in Pleasanton, California, has raised over $111M-$285M across multiple rounds, remains operational post-acquisition financing, and generates approximately $46M in revenue while holding 22 patents in molecular biology and biotechnology.[1][5]
Unchained Labs emerged in 2014-2015 in Pleasanton, California, with a focus on addressing pain points in biologics research, starting with the Optim platform—the world's first multiplex protein stability tool for biologists.[1][5][6] Founders and early team honed in on "finicky" biologics molecules requiring precise formulation for stability, expanding into gene therapy complexities like virus and nanoparticle payloads.[3][6] Early traction came from innovative products tackling stability, aggregation, and quantification, leading to rapid growth, substantial funding (including a $155M recent round), and patent filings in cell biology and biotech, positioning it as a problem-solving force in life sciences.[1][5]
Unchained Labs rides the explosive growth in biologics and gene therapy, fueled by mRNA vaccines, AAV vectors, and LNPs post-COVID, where demand for precise characterization has surged amid complex delivery challenges.[2][4][6] Timing aligns with a market shift from traditional small molecules to these "uber complicated" modalities, where outdated tools fail—Unchained's efficient, non-destructive platforms accelerate R&D pipelines for pharma and biotech.[1][3] It influences the ecosystem by enabling faster iteration in cell/gene therapies and vaccines, supporting academic-to-commercial translation, and fostering innovation through webinars, events, and a "tribe" community.[3]
Unchained Labs is primed to dominate as the go-to supplier for biologics/gene therapy tools, with expansions like the Sunny Suite for LNPs signaling deeper penetration into booming vaccine and personalized medicine markets.[3][5][6] Trends like AI-driven automation, rising CRISPR/RNA therapies, and regulatory pushes for scalable manufacturing will amplify demand for their workflow-crushing tech. Expect further acquisitions, global scaling, and patent-driven moats, solidifying their role in unleashing breakthrough science from lab constraints—echoing their founding promise to break free from inadequate tools.[1][4]
Unchained Labs has raised $80.0M across 4 funding rounds. Most recently, it raised $17.0M Series D in March 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2018 | $17.0M Series D | Canaan Partners, Norwest Venture Partners | |
| Jun 1, 2017 | $13.0M Series C | Canaan Partners, Norwest Venture Partners | |
| Feb 1, 2016 | $25.0M Series B | Canaan Partners, Norwest Venture Partners | |
| Feb 1, 2015 | $25.0M Series A | Canaan Partners, Norwest Venture Partners |